Treatment of HCC with pravastatin, octreotide, or gemcitabine--a critical evaluation.

Abstract

These results do not confirm those of former studies. Neither pravastatin, nor octreotide, nor gemcitabine did prolong the patients' median overall survival as compared to control groups reported by other authors. New therapeutic strategies have to be found for patients with advanced hepatocellular carcinomas.